Defence Announces Closing of Securities for Debenture Financing

Core Points - Defence Therapeutics Inc. has closed an offering of unsecured convertible debentures for gross proceeds of CAD$1,476,000 to settle outstanding debt from previous debentures [1][2] - The new debentures bear an interest rate of 8.0% per annum, mature on November 16, 2025, and are convertible into common shares at a price of $0.60 per share [2][3] - The total accrued interest of approximately $251,200 from previous debentures was settled by converting it into common shares at a price of $0.57 per share, resulting in the issuance of 440,697 common shares [4][5] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing radio-immuno-conjugate and ADC products, utilizing its proprietary ACCUM® technology for precision delivery [6]